Peptide Aggregation & Fibrillation

Peptide aggregation is the process by which individual peptide molecules associate to form larger multi-molecular assemblies — from small soluble oligomers to visible precipitates to highly ordered amyloid-like fibrils. It is one of the most common causes of potency loss in reconstituted peptide solutions and represents a distinct degradation pathway from chemical decomposition. The peptide's primary structure remains intact, but the molecules become biologically unavailable because they are locked into intermolecular assemblies.

Mechanisms of aggregation

Aggregation proceeds through a nucleation-dependent pathway resembling crystallization. In the lag phase, individual monomers undergo partial unfolding or conformational change, exposing hydrophobic regions or beta-sheet-prone backbone segments. These intermediates associate transiently to form small, unstable oligomers.

Once a critical nucleus forms — typically 4 to 12 monomers — the process enters rapid growth. The nucleus acts as a template, recruiting additional monomers into an extending structure. This growth phase can convert a significant fraction of soluble peptide into aggregates within hours.

Final structures vary. Amorphous aggregates lack regular internal order — disordered clumps held by hydrophobic interactions. Amyloid-like fibrils have a characteristic cross-beta structure where beta-strands from successive molecules run perpendicular to the fibril axis, forming a continuous hydrogen-bonded sheet. Many peptides can form both types depending on conditions.

Some peptides aggregate through native-state association without unfolding, where intact molecules cluster through complementary surface interactions. This is common with peptides that have exposed hydrophobic patches or at high concentrations where collision frequency overwhelms the solubility limit.

Conditions that promote aggregation

Concentration. Higher concentration increases intermolecular contacts. Most peptides have a critical aggregation concentration (CAC) — as low as 0.1 mg/mL for aggregation-prone sequences — below which they remain monomeric.

Temperature. Heat accelerates aggregation by increasing collision frequency and promoting partial unfolding. However, repeated freeze-thaw cycles also promote aggregation by concentrating peptide at ice-crystal boundaries.

pH. Near the isoelectric point (pI), where net charge approaches zero, electrostatic repulsion is minimized and aggregation is most favorable. Moving pH away from pI improves solubility.

Ionic strength. Moderate salt can screen electrostatic repulsion, promoting aggregation of charged peptides.

Agitation. Shaking, vortexing, and syringe pumping introduce air-water interfaces where peptides adsorb, partially unfold, and nucleate aggregation. This is a significant and often underappreciated source of aggregation in practical handling.

Surface adsorption. Peptides adsorb to glass, plastic, and rubber surfaces. Conformational changes at these interfaces can seed aggregation, causing apparent potency loss even without chemical degradation.

Detecting aggregation

Visual inspection reveals only advanced aggregation — particles, turbidity, or gelation. Sub-visible aggregates and soluble oligomers require analytical methods. In practice, the most accessible indicators are changes in appearance (cloudiness, visible particles, increased viscosity) in a previously clear solution. Reduced biological potency without chemical explanation (stable on mass spectrometry or HPLC) also suggests aggregation.

Practical approaches to minimize aggregation

Reconstitute to appropriate concentration. Use sufficient diluent to keep concentration below the critical aggregation threshold. For most research-grade peptides, concentrations below 1 mg/mL carry less aggregation risk.

Use appropriate diluent. Bacteriostatic water is standard. For aggregation-prone peptides, buffered solutions at pH away from pI improve stability. Low concentrations of non-ionic surfactants (polysorbate 20 or 80) compete for air-water interfaces and reduce surface-mediated nucleation.

Minimize agitation. Direct diluent gently down the vial wall and dissolve by gentle swirling rather than vigorous shaking. Avoid repeatedly drawing and expelling through syringe needles.

Store at appropriate temperature. Refrigeration (2 to 8 degrees Celsius) slows aggregation kinetics. Avoid repeated freeze-thaw cycles — aliquot into single-use volumes before freezing.

Minimize storage duration. Even under optimal conditions, aggregation progresses over time. Any solution showing visible changes should be discarded.

Sequence determinants of aggregation propensity

Shorter peptides (under 10 amino acids) are generally less prone to fibril formation than longer sequences, though they can still form amorphous aggregates. Peptides with alternating hydrophobic and hydrophilic residues are particularly susceptible to beta-sheet-driven fibrillation. Proline residues, which disrupt beta-sheet structure, confer protection when present in the sequence. Insulin is perhaps the most studied aggregation-prone peptide — insulin fibrillation in pump cartridges held at body temperature under agitation has driven extensive formulation research applicable to other peptide therapies.